The US Food and Drug Administration (FDA) has approved Pixyl’s AI brain MRI analysis software, Pixyl.Neuro.
The software increases detection rates by up to 28%, according to the company. It quantifies and compares MRI findings to identify abnormal atrophy earlier and aid diagnosis, the company said.
Facilities in more than a dozen countries in Europe, North America and Africa use Pixyl.Neuro, Pixyl said.
